Article Figures & Data
Tables
- Table 1.
Surveillance Epidemiology and End Results Age-Adjusted Childhood Cancer Incidence* among the US Population for All Races and Sexes, 2002 to 2006 by Primary Cancer Site3
Incidence by Age 0–14 Years 0–19 Years All sites, all races 15.1 16.6 Leukemia 5.0 4.5 Acute lymphoblastic leukemia 4.0 3.4 Brain and nervous system 3.2 2.9 Hodgkin lymphoma 0.6 1.2 Soft tissue 1.0 1.1 Non-Hodgkin lymphoma 0.9 1.1 Bone and joint 0.7 0.9 Kidney and renal pelvis 0.8 0.6 * Rates are per 100,000 and are age-adjusted to the 2000 US population.
- Table 2.
Surveillance Epidemiology and End Results Age-Adjusted Childhood Cancer Death Rates* among the US Population for All Races and Sexes, 1975 and 2006 by Primary Cancer Site
Death Rates by Age 0–14 Years 0–19 Years 1975 2006 1975 2006 All sites, all races 4.9 2.2 5.1 2.5 Brain and nervous system 1.0 0.6 0.9 0.7 Leukemia 2.1 0.7 2.0 0.7 Acute lymphoblastic leukemia 1.2 0.3 1.0 0.3 Soft tissue 0.1 0.1 0.2 0.2 Kidney and renal pelvis 0.2 0.1 0.1 0.1 Non-Hodgkin lymphoma 0.4 0.1 0.4 0.1 Hodgkin lymphoma 0.0 — 0.1 0.0 * Rates are per 100,000 and are age-adjusted to the 2000 US population.
- Table 3.
Surveillance Epidemiology and End Results 5-Year Survival Rates* among the US Population, 1975 to 1977 and 1999 to 2005, by Selected Primary Cancer Site
Survival Rates by Age (%) 0–14 Years 0–19 Years 1975–1977 1999–2005 1975–1977 1999–2005 All sites, all races 58.1 81.3 61.6 81.0 Hodgkin lymphoma 80.5 95.4 86.0 95.5 Wilms tumor 73.1 91.2 72.6 91.2 Acute lymphoblastic leukemia 57.6 89.0 54.1 85.1 Non-Hodgkin lymphoma 43.5 86.3 44.6 84.4 Leukemia 50.4 83.6 45.5 78.7 Soft tissue 61.0 81.0 65.2 75.6 Brain and central nervous system 56.9 73.8 58.8 74.2 Neuroblastoma 52.4 74.2 52.7 73.9 Bone and joint 49.9 71.8 50.4 68.5 Acute myeloid leukemia 18.8 60.2 18.7 55.0 * Rates are based on follow-up of patients into 2006.
- Table 4.
Childhood Cancers in Diagnostic Groups According to the International Classification of Childhood Cancer14
Classification Type(s) of Cancer I Leukemias, myeloproliferative, and myelodysplastic diseases II Lymphomas and reticuloendothelial neoplasms III Central nervous system and other intracranial and intraspinal neoplasms IV Neuroblastoma and other peripheral nervous cell tumors V Retinoblastoma VI Renal tumors VII Hepatic tumors VIII Malignant bone tumors IX Soft tissue and other extraosseous sarcomas X Germ cell tumors, trophoblastic tumors, and neoplasms of gonads Complication Surveillance Treatment Modality Growth failure History/examination Chemotherapy Cranial radiation Intellectual function Psychiatric test Cranial radiation Neurological toxicity Neurologic examination Cranial radiation Vincristine Dental Examination Chemotherapy Cleaning Cranial radiation Male infertility LH, FSH Abdominal/pelvic radiation Testosterone Cyclophosphamide Sperm count Doxorubicin/daunomycin Female infertility LH, FSH Abdominal/pelvic radiation Estradial Cyclophosphamide Doxorubicin/daunomycin Cardiac ECG, echocardiogram Doxorubicin/daunomycin Bladder Urinalysis Cyclophosphamide Ifosphamide Lung Chest radiograph Buslfan Liver LFTs Methotrexate Bone DEXA scan Prednisone/dexamethasone Methotrexate Eye (cataracts) Visual acuity Prednisone/dexamethasone Ear (hearing) Audiogram Cisplatinum/carboplatinum Second neoplasms Examination Radiation Blood count Cyclophosphamide Urinalysis Doxorubicin/daunomycin Recurrence History/examination * As recommended in “Long-Term Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers,” published by the Children's Oncology Group in 2008 (www.survivorshipguidelines.org).
LH, luteinizing hormone; FSH, follicle-stimulating hormone; ECG, electrocardiogram; LFT, liver function test; DEXA, dual energy x-ray absorptiometry.
